ASAM Pain and Addiction: Common Threads Course XXV - 2024

Dr Rudolf is a physician board certified in addiction medicine, pain medicine, medical acupuncture and family medicine practicing at Swedish Pain Services in Seattle. The clinic integrates multidisciplinary pain care approaches in an effort to optimize patient functional outcomes and self-efficacy. He has also worked extensively in inpatient substance use disorder treatment settings and has published on the topic of opioid withdrawal management. He is the current Chair of the ASAM Pain and Addiction Committee, the immediate past president of the Washington Society of Addiction Medicine, and is a clinical associate professor at University of Washington.

Dr. Mark Sullivan received his M.D. and his Ph.D. in Philosophy from Vanderbilt University. After completing an internship in Family Medicine at University of Missouri, he completed a residency in Psychiatry at the University of Washington in 1988. He is now Professor of Psychiatry and Behavioral Sciences as well as Adjunct Professor of Anesthesiology and Pain Medicine and Adjunct Professor of Bioethics and Humanities at the University of Washington. He has served as attending physician in the UW Center for Pain Relief for over 25 years, where he is Co-Director of Behavioral Health Services. He has published over 240 peer-reviewed articles, many on chronic pain. He is currently participating in NIMH, NIDA, CDC, PCORI and VA-funded studies on opioid therapy for chronic pain. He has been chair of the Ethics Committee of the American Pain Society and on the editorial board of Pain. He has a book forthcoming from Oxford University Press titled, The Patient as Agent of Health and Health Care.

Roger Chou is a Professor in the Department of Medical Informatics & Clinical Epidemiology and the Department of Medicine at Oregon Health & Science University (OHSU) School of Medicine and Director of the Pacific Northwest Evidence-based Practice Center. His clinical background is general internal medicine. He has authored over 300 peer-reviewed articles, including numerous systematic reviews, and led or participated in clinical guideline development efforts in chronic pain and opioids, low back pain, addiction, and other topics, and is among the top 2% cited scientists in the world. His reviews have been used by the American College of Physicians, the Centers for Disease Control and Prevention, the US Preventive Services Task Force, the American Pain Society, the American Urological Association, the World Health Organization, and others to develop clinical practice guidelines. Dr. Chou serves as a methodologist for several World Health Organization guideline development groups, served as Coordinating Editor of the Cochrane Back and Neck and Senior Editor of Cochrane Musculoskeletal, and serves on the Board of Scientific Counselors of the CDC’s National Centers for Injury Prevention and Control.

Dr. Martin Cheatle is an Associate Professor of Psychiatry, Anesthesiology, and Critical Care, Director of Behavioral Medicine at the Penn Pain Medicine Center, and Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction, Perelman School of Medicine at the University of Pennsylvania. He has been conducting research and providing clinical treatment of patients with chronic pain and co-morbid disorders including substance use disorders, HIV, mood disorders, and sleep disorders as director of both university and community-based interdisciplinary pain programs.  His focus of research is in improving pain care to individuals from vulnerable populations (psychiatric, substance use disorders, HIV, sleep disorders) including developing strategies to identify and mitigate the risks associated with opioid therapy and the risk of suicide in the pain population. He was the PI of a recently completed RO1 NIDA grant on clinical and genetic characteristics of opioid addiction in chronic pain; a project PI of a NIDA P-60 Center grant on a longitudinal study of the development of a substance use disorder in patients initiating prescription opioid therapy for chronic pain in primary care; and as a co-investigator in the development of a patient-centered medical home model for improved pain care.  Currently, Dr. Cheatle is a co-investigator of many recently funded NIH grants examining the effect of cognitive behavioral therapy delivered preoperatively to patients undergoing total knee arthroplasties in reducing postoperative pain, opioid use, and the chronification of pain.

Dr. Manhapra completed his M.B.B.S. degree from Government Medical College, Thrissur, India and Internal Medicine residency from Henry Ford Hospital, Detroit, MI. He was a practicing internist for over a decade and then completed VA Advanced Inter-professional Fellowship in Addiction Treatment at West Haven VA Medical center, CT, affiliated to Department of Psychiatry, Yale School of Medicine. He has been a clinician, researcher and scholar focused on recovering people with pain and addiction for the past decade. He is currently the Section Chief of Pain Medicine at Hampton VA Medical Center, Hampton, Virginia and runs an interdisciplinary clinic helping people with complex chronic pain and multimorbidity find a path to functional recovery. Dr. Manhapra and colleagues pioneered the concept of complex persistent opioid dependence/opioid induced chronic pain as an explanation of ineffectiveness of long term opioid therapy and its deprescribing. Dr. Manhapra also advanced the treatment of ineffective long term opioid therapy and failed opioid taper using buprenorphine based pharmacobehavioral approaches. 

Mark C. Bicket, MD, PhD is an Associate Professor in the Department of Anesthesiology at the University of Michigan School of Medicine. He has a joint appointment at the University of Michigan School of Public Health. He received an M.D. and a Ph.D. in Clinical Investigation from the Johns Hopkins University. He completed anesthesiology residency at the Johns Hopkins Hospital, where he served as Chief Resident and pain medicine fellowship training at the Massachusetts General Hospital.

Dr. Bicket has research interests in improving the care for patients in the perioperative setting and with acute or chronic pain. He serves as Co-Director of the Overdose Prevention Engagement Network, a group dedicated to advancing evidence, resources, and engagement to address the overdose epidemic. In the Department of Anesthesiology, he serves as Director for Opioid Research. A clinician-scientist and practicing physician anesthesiologist, his work has been supported by NIH, SAMHSA, FDA, CDC, and the Patient-Centered Outcomes Research Institute (PCORI). He is the Principal Investigator of two PCORI-funded clinical trials, including Comparing Analgesic Regimen Effectiveness and Safety (CARES), an international pragmatic randomized trial to examine the association between commonly prescribed treatments for postoperative pain with patient-reported outcomes at up to 6 months after surgery. Dr. Bicket has served on committees for the National Academy of Medicine, Centers for Medicare and Medicaid Services, state governments, and national organizations.

Deondra Asike, MD is double board certified in anesthesiology and pain medicine. She is a Clinical Associate in the Department of Anesthesiology and Critical Care Medicine at Johns Hopkins since 2015. She is a veteran of the United States Air Force and deployed to Bagram Air Base, Afghanistan in 2013.  She received her medical degree at Georgetown University School of Medicine. Dr. Asike completed her anesthesiology residency at the San Antonio Military Medical Center and fellowship training in pain medicine at the University of Maryland.  Dr. Asike is currently serving a second term on the Maryland Department of Health Prescription Drug Monitoring Program Advisory Board. Additionally, she chairs the Maryland Cannabis Public Health Advisory Council and The Maryland State Medical Society Cannabis Committee.  She is a specialty expert and Maryland Spokesperson for Doctors For Drug Policy Reform, the nation’s first physician organization dedicated to the legalization, taxation, and effective regulation of cannabis for adults. She believes strongly in a holistic approach to chronic pain management that includes proper nutrition, physical therapy, behavioral therapy, and cannabis as medicine. Dr. Asike is a certifying provider with the Maryland Cannabis Administration. In 2022 she founded National Pain ReLEAF, a consultation practice primarily focused on guiding both patients and members of their healthcare team through a safe and effective incorporation of cannabis into a comprehensive pain treatment.

Jeff Boissoneault, PhD serves as an Associate Professor in the Department of Anesthesiology at the University of Minnesota, where he directs the Minnesota Alcohol and Pain Lab (MAPL). Dr. Boissoneault’s research interests focus on neurophysiological and psychosocial mechanisms underling the bidirectional association between pain and substance use, especially alcohol. He is also actively involved in studies regarding cortical-brainstem-spinal interactions underlying placebo analgesia and non-pharmacologic approaches to improve pain modulatory capacity in people with chronic widespread musculoskeletal pain. He received his doctorate in medical sciences with a concentration in cognitive/behavioral neuroscience from the University of Florida and completed a postdoctoral fellowship in pain research in the University of Florida’s Pain Research and Intervention Center of Excellence. 

Emmanuelle Schindler, MD, PhD is Medical Director of the Headache Center of Excellence at Veterans Affairs (VA) Connecticut Healthcare System and Assistant Professor of Neurology at Yale School of Medicine. She is a board-certified Neurologist and Headache Medicine specialist. Among her efforts to optimize the management of headache disorders, she has executed the first controlled trials of psilocybin in cluster, migraine, and post-traumatic headache. Previously, Dr. Schindler studied the neuropharmacology of psychedelics and other serotonergic compounds in the context of receptor binding and intracellular signaling at Drexel University College of Medicine. Her neuropharmacology background frames her endeavor to investigate the potential for psychedelics to serve as safe and effective headache medicines. Currently, she seeks to identify the source of sustained reductions in headache burden after limited dosing of psilocybin, considering several neurobiological systems. 

Dr. Orman Trent Hall is an assistant professor of Addiction Medicine in the Department of Psychiatry and Behavioral Health at The Ohio State University Wexner Medical Center (OSUWMC) and The Ohio State University College of Medicine. Dr. Hall completed residency in Physical Medicine & Rehabilitation at the University of Michigan, as well as Addiction Medicine fellowship and a postdoctoral research fellowship in Addiction Neuroscience at The Ohio State University. He now directs a hospital-based Addiction Medicine Consult Service at OSUWMC and co-leads the Healthy State Alliance Addiction Initiative – a strategic partnership between OSUWMC and Bon Secours Mercy Health that combats the addiction crisis in Ohio through collaboration in education, clinical care, advocacy, and research. Dr. Hall’s research is focused on improving the treatment of substance use disorders through clinical phenotyping. Specifically, his research aims to identify subgroups of patients with comorbid chronic pain and substance use disorders for whom central nervous system mechanisms play a prominent role in connecting their pain and addiction.